Ann: Dispatch of Shareholder Circular, page-32

First 32 Last

Share
Profile

Follow
GTyson

57 Posts.

22

03/10/18

20:40

Post #: 35984385
Share

Originally posted by Macleod22 ↑

Steven,

Whatever I state must be tested in a court of law. In my opinion evidence suggests that the Tubatse shares should have been cancelled because the two farms were lost. The 250m NKP shares plus cash was given to Genorah in exchange for the three farms. That is a fact. The NKP/ Genorah directors who were also shareholders enjoyed the benefits of the transaction.

Facts suggest that the shares were exchanged while the farms were disputed in court by the Bengwenyama. If so why did the NKP directors allocate the shares if there was a possibility of the farms being lost? Was it because they were also beneficiaries via Genorah?

Move along in time and ask yourself why were the 250m shares placed in escrow before conclusion of the court case? No info shared with shareholders re this. Why were the shares removed from escrow? On what basis?

So the farms were lost and NKP got SFA while Genorah got shares for nothing which they then on sold to Zijin.

Both ASX and ASIC refuse to investigate the transaction. This is called justice. What more can I say?

I have presented facts with relevant links and time lines. Why will no one investigate? I rest my case. Ask the polititions to perform their duties on behalf of Australian investors.

If Genorah had not received those shares to sell to Z, Zijin's holding would be closer to 40% and not 60%.

Dr Tan refuses to reply why the shares were not cancelled. I refer you to the 2016 SGM.

Expand

Mac, have you looked at the current terms of reference of the present Royal Commission as to whether a submission is possible under any category? I noticed that submissions are being accepted 'till the end of October. The NKP situation stinks, and while I agree that we have no choice but to pursue the dissenting shareholder path (given the time constraints), there is no reason why a separate submission could not be made to the commission (if applicable).

How did you go with the ABC (Four Corners)? Did you receive a reply?

NKP Price at posting: 9.0¢ Sentiment: Hold Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

BUX

Buxton projects new graphite province discovery at WA Narryer play

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 1 more message in this thread...

First 32 Last

Add NKP (ASX) to my watchlist

Ann: Dispatch of Shareholder Circular, page-32

Top Stories

BCI reaches close of funding facility for salt-first part of Mardie project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Buxton projects new graphite province discovery at WA Narryer play

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News